Death receptors as targets in cancer

Anti-tumour therapies based on the use pro-apoptotic receptor agonists, including TNF-related apoptosis-inducing ligand (TRAIL) or monoclonal antibodies targeting TRAIL-R1 or TRAIL-R2, have been disappointing so far, despite clear evidence of clinical activity and lack of adverse events for the vast...

Full description

Saved in:
Bibliographic Details
Main Authors: Micheau, O, Shirley, S, Dufour, F
Format: Artigo
Language:Inglês
Published: Blackwell Publishing Ltd 2013
Subjects:
Emerging Therapeutic Aspects in Oncology Themed Section
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3753832/
https://ncbi.nlm.nih.gov/pubmed/23638798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.12238
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items